PS-341 in Combination With Herceptin in Advanced Breast Cancer That Overexpresses HER-2
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The main objective of this study is to determine the feasibility of the combination of the
proteasome inhibitor bortezomib (PS-341, Velcade) with trastuzumab (Herceptin) and to
determine the best dose of bortezomib to combine with two trastuzumab schedules, weekly and
3-weekly.